Logo
Arrow
Xceed LoginConnect Now
Logo
Arrow
Arrow

Finished Dosage Forms - Product List:

Dr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.

Search
Therapy Areaarrow
Dosage Formarrow
Dossier Statusarrow
Therapy AreaProduct NameOralInjStrengthDossier StatusConnect
抗糖尿病Sitagliptin HCL + MetforminTick50 + 500, 50 + 850開発中でEnvelope
抗糖尿病Sitagliptin HCLTick25, 50, 100 mgFiledEnvelope
抗糖尿病Sitagliptin PhosphateTick25, 50 and 100 mgFiledEnvelope
抗糖尿病Sitagliptin Phosphate + MetforminTick50 + 500, 50 + 1000 mgFiledEnvelope
心臓血管EltrombopagTick12.5, 25, 50 and 75 mgFiledEnvelope
心臓血管Bempedoic acid EzetimibeTick180 mg/10 mg開発中でEnvelope
心臓血管Bempedoic acidTick120 mg and 240 mg開発中でEnvelope
心臓血管EdoxabanTick15 mg, 30 mg and 60 mg開発中でEnvelope
心臓血管Tafamidis MeglumineTick20 mg開発中でEnvelope
中枢神経系VigabatrinTickUSP 500 mgFiledEnvelope
中枢神経系Edaravone60 mg/100 mlFiledEnvelope
中枢神経系Topiramate ERTick25, 50, 100 and 200 mgFiledEnvelope
中枢神経系CarboprostTickUSP Inj 250 mcg/ml PFSFiledEnvelope
中枢神経系ColchicineTick0.6 mgFiledEnvelope
中枢神経系Dimethyl FumarateTick120 mg and 240 mg開発中でEnvelope
腫瘍学Busulfan6 mg/ml (10 ml)FiledEnvelope
腫瘍学PazopanibTick200 and 400 mg開発中でEnvelope
腫瘍学Bendamustine RTD45 mg/ml (4 ml) and 25 mg/ml (4 ml)FiledEnvelope
腫瘍学Bortezomib3.5 mgFiledEnvelope
腫瘍学FingolimodTick0.5 mgFiledEnvelope
Page 1 of 2

Product Capabilities

1R&D and Manufacturing Capabilities
Toggle
Research and DevelopmentManufacturing FacilitiesNich Product OpportunitiesVertical Integration
4 State-of-the-art R&D centres in India, U.K., U.S., and Netherlands 1200+ research scientists working on various projects11 formulations manufacturing facilitiesPeptides, Prostaglandins, HPAPIs, Innovative drug delivery, Novel dosage forms, Complex InjectablesMore than 60% of our formulations are backward integrated with our In- house API

Our 11 formulations manufacturing facilities that are operated in accordance with cGMP (ICH Q7a) and regularly inspected/audited by international regulatory authorities and customers (USFDA, MHRA, EMA, PMDA, TGA, SAHPRA, ANVISA, Russian MoH, CFDA, COFEPRIS and Health Canada).

2Product Capabilities
Toggle

Dr. Reddy's has an expertise of developing and manufacturing various dosage forms:

Oral SolidsInjectablesNovel Dosage Forms
Tablets, Chewable tablets, OrodispersibleLyophilized product and Liquid solutionEmulsions, Suspensions, Microspheres Liposomes tablets, Capsules, soft gel capsules Pellets a and Nanoparticles
3Service Capabilities
Toggle

Highly experienced and integrated technical team to support from filing-to-launch. Highly experienced technical and global regulatory teams with experience of 350+ Filings and 150+ approvals across B2B markets.

Regulatory servicesTech Transfer supportBio Study design support
Team of regulatory expertsComplete knowledge transferClinical pharmacokinetic team available
Support filing activitiesSupport local manufacturingDesign bio study protocol

Across multiple countries of interest

製品の専門家と1対1のバーチャルセッションでお会いしましょう

当社の専門家がご質問にお答えし、アドバイスやグローバルジェネリック情報、納期についてご説明し、製品への理解を深めていただけます

折り返し電話をリクエストbutton arrow
meet with img
alt
alt

Global Presence

alt
  • altEurope
  • altMexico
  • altArgentina
  • altTurkey
  • altMena
  • altNorth Asia

Re-imagine API sourcing with Dr. Reddy's

免責事項

このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.